Vanda Pharmaceuticals Inc. (VNDA) Stock Forecast
VNDA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $11.75 average of analyst targets
- Upside to target
- +191.6% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.72
- 52-week range
- $4.03 – $9.56
VNDA analyst ratings
5 analystsNumber of analysts at each rating.
VNDA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VNDA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.68 | −$0.83 | −$0.58 | −$0.38 | −79.5% | 5 |
| Current fiscal year (2026) | −$3.03 | −$3.08 | −$2.92 | −$3.74 | +19.0% | 5 |
| Next fiscal year (2027) | −$0.96 | −$1.38 | −$0.67 | −$3.03 | +68.4% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VNDA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $69.1M | $60.8M | $76.0M | +22.9% | 5 |
| Current fiscal year (2026) | $248.9M | $240.2M | $262.0M | +15.2% | 5 |
| Next fiscal year (2027) | $337.2M | $305.0M | $370.0M | +35.5% | 5 |
VNDA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VNDA revenue: reported and forecast
VNDA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.59 | −$0.68 | −$0.68 | −$0.68 | +34.4% | 0 up · 4 down |
| Current fiscal year (2026) | −$2.27 | −$3.06 | −$3.02 | −$3.03 | −$3.03 | +33.6% | 0 up · 4 down |
| Next fiscal year (2027) | −$0.77 | −$0.88 | −$1.03 | −$0.96 | −$0.96 | +24.4% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VNDA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VNDA beat in 7 of 12.
What analysts expect from VNDA
5 analysts cover Vanda Pharmaceuticals; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.75, 191.6% above the latest close of $4.03. Analysts expect earnings of −$3.03 per share for 2026, +19.0% from a year earlier. For 2027 the average estimate is −$0.96 per share on revenue of $337.2 million. Vanda Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: VNDA income statement, VNDA key metrics, VNDA chart. See the VNDA stock overview for the latest quote and news.
VNDA forecast FAQ
What is Vanda Pharmaceuticals's price target?
The average analyst price target for Vanda Pharmaceuticals is $11.75, 191.6% above the latest close of $4.03.
Is Vanda Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering Vanda Pharmaceuticals, 4 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vanda Pharmaceuticals's EPS forecast?
Analysts forecast −$3.03 per share for 2026 (range −$3.08 to −$2.92); for 2027 the estimate is −$0.96.
What is Vanda Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $248.9 million, growth of 15.2%; for 2027 it is $337.2 million.
When does Vanda Pharmaceuticals report earnings?
Vanda Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.72.
Does Vanda Pharmaceuticals usually beat earnings estimates?
Vanda Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.